Loading...
India's pantoprazole imports from ROMANIA total $32 across 3 shipments from 1 foreign suppliers. ZENTIVA S.A leads with $32 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include ZENTIVA PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for pantoprazole — a concentrated sourcing relationship with select suppliers from ROMANIA.
ZENTIVA S.A is the leading Pantoprazole supplier from ROMANIA to India, with import value of $32 across 3 shipments. The top 5 suppliers — ZENTIVA S.A — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ZENTIVA S.A | $32 | 3 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ZENTIVA PRIVATE LIMITED | $32 | 3 | 100.0% |
ROMANIA → India trade corridor intelligence
The Romania to India trade corridor for pharmaceutical imports, including finished Pantoprazole formulations, is currently stable. Major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with no significant congestion reported. Freight rates have remained consistent over the past year, and the exchange rate between the Indian Rupee (INR) and the Romanian Leu (RON) has shown minimal fluctuation, ensuring predictable costs for importers. The logistics infrastructure supports timely deliveries, and there are no major disruptions affecting the supply chain.
The Indian government's Production-Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce reliance on imports. While the PLI scheme primarily targets the production of active pharmaceutical ingredients (APIs) and bulk drugs, its impact on finished formulation imports, such as Pantoprazole, is limited. Import substitution policies are being considered to encourage domestic production of certain formulations; however, the specialized nature of some products may continue to necessitate imports. The balance between promoting self-reliance and meeting market demand will influence future import trends.
India and Romania maintain a cordial trade relationship, with ongoing discussions to enhance bilateral trade, including in the pharmaceutical sector. While there is no Free Trade Agreement (FTA) between the two countries, both nations are exploring avenues to facilitate trade through mutual recognition of Good Manufacturing Practice (GMP) certifications and streamlined import procedures. These efforts aim to simplify the import process for pharmaceutical products and strengthen trade ties.
The landed cost of importing finished Pantoprazole formulations from Romania to India includes several components:
The total landed duty percentage is approximately 17.10%. Per-unit estimates depend on the volume and value of the shipment, as well as the specific terms negotiated with suppliers and logistics providers.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Pantoprazole into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting detailed product information, including manufacturing details, quality control measures, and clinical data. The registration certificate is valid for three years from the date of issue. The Import License, issued by the Drug Controller General of India (DCGI), is also valid for three years. The application process typically takes several months, depending on the completeness of the submitted documentation and the CDSCO's evaluation process. For Pantoprazole formulations under HS Code 30049039, the manufacturer must provide a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certification, and stability data demonstrating the product's shelf-life under Indian conditions. Additionally, a No Objection Certificate (NOC) from the manufacturer may be required. The timeline for obtaining these approvals can vary but generally ranges from six months to a year.
Imported finished pharmaceutical formulations containing Pantoprazole must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with the Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV conditions, must be provided to demonstrate the product's stability in India's climate. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. The batch testing process can take several weeks, depending on the laboratory's workload and the complexity of the tests required.
In April 2025, the Indian government introduced new regulations requiring import registration and licenses for all imported medicines, including finished pharmaceutical formulations. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. The Central Drugs Standard Control Organization (CDSCO) emphasized that both the Import Registration Certificate and Import License are mandatory for importing drugs into India. These measures are part of a broader effort to streamline the import process and ensure that all imported pharmaceutical products meet India's quality, safety, and efficacy standards. The implementation of these regulations is expected to enhance the integrity of the pharmaceutical supply chain and protect public health.
Market demand, customs duty structure, and competitive landscape · Import duty: 17.10%
India imports finished Pantoprazole formulations to meet the demand for branded and patented products, as well as specific dosage forms not produced domestically. The domestic pharmaceutical industry may lack the capacity to manufacture certain specialized formulations, leading to reliance on imports. Pantoprazole is widely used for treating gastroesophageal reflux disease (GERD) and other acid-related disorders, contributing to its significant market presence. The market size for Pantoprazole formulations in India is substantial, with imports playing a crucial role in fulfilling the demand for diverse formulations.
The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049039 is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% is applied on the BCD. The Integrated Goods and Services Tax (IGST) is levied at a rate of 12% on the total value, including the BCD and SWS. There are no additional duties such as Countervailing Duty (CVD) or National Calamity Contingent Duty (NCCD) applicable to this product category. Exemptions or concessional rates may apply under specific trade agreements or government notifications, but these are subject to change and should be verified with the latest customs notifications. The total landed duty percentage, combining all applicable duties and taxes, is approximately 17.10%.
India sources finished Pantoprazole formulations from Romania due to the country's competitive advantages, including adherence to Good Manufacturing Practice (GMP) standards and the ability to supply specialized dosage forms not readily available domestically. Romania's pharmaceutical industry is known for its quality manufacturing processes and compliance with international standards, making it a reliable source for importing finished formulations. Other suppliers, such as China, Germany, and the United States, also contribute to India's Pantoprazole import market. However, Romania's specific offerings and quality standards position it favorably in the competitive landscape.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Pantoprazole formulations from Romania due to the country's ability to supply specialized dosage forms and formulations not readily available domestically. Romania's pharmaceutical industry adheres to stringent quality standards, ensuring the safety and efficacy of the products. The importation of these formulations allows Indian pharmaceutical companies to offer a broader range of products to meet diverse patient needs.
When compared to other sources such as China, Germany, and the United States, Romania offers competitive pricing and high-quality manufacturing standards. Romanian pharmaceutical products are known for their compliance with international regulations and quality assurance processes. While other countries may offer lower prices or different formulations, Romania's consistent quality and reliability make it a preferred choice for importing finished Pantoprazole formulations.
Potential risks for Indian importers include reliance on a single source, currency fluctuations, regulatory changes, and shipping disruptions. Diversifying suppliers and maintaining adequate inventory levels can mitigate some of these risks. Regular communication with Romanian suppliers and staying informed about regulatory developments in both countries are essential for proactive risk management.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Pantoprazole suppliers from ROMANIA to India include ZENTIVA S.A. The leading supplier is ZENTIVA S.A with import value of $32 USD across 3 shipments. India imported Pantoprazole worth $32 USD from ROMANIA in total across 3 shipments.
India imported Pantoprazole worth $32 USD from ROMANIA across 3 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Pantoprazole sourced from ROMANIA include ZENTIVA PRIVATE LIMITED. The largest buyer is ZENTIVA PRIVATE LIMITED with $32 in imports across 3 shipments.
The total value of Pantoprazole imports from ROMANIA to India is $32 USD, across 3 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists